WASHINGTON (Reuters) - The U.S. Department of Veterans Affairs (VA) has treated 1,300 coronavirus patients with the malaria drug hydroxychloroquine, which a study has tied to an increased risk of death, according to a document released by a Senate Democrat on Friday.
Senate Democratic Leader Chuck Schumer, who received the information from the VA in response to questions he submitted on the issue, said he was “deeply troubled” by the data.
President Donald Trump has long urged use of hydroxychloroquine against coronavirus and recently said he has been taking it himself, despite evidence that the treatment could be harmful.
A study published on Friday in the medical journal Lancet tied the drug to an increased risk of death in hospitalized patients with COVID-19, the disease caused by the novel coronavirus.
In April, doctors at VA itself also said hydroxychloroquine did not help COVID-19 patients and might pose a higher risk of death.
The VA, which provides care to 9 million veterans, said that about 1,300 coronavirus patients who received the drug are among more than 10,000 COVID-19 patients it has treated. It has also dispensed hydroxychloroquine to about 7,500 patients with other conditions including rheumatoid arthritis and lupus.
The VA said it will continue to dispense the drug under the guidelines of the Food and Drug Administration.
In answer to a question from Schumer, the VA said it was not pressured into using hydroxychloroquine by the White House, the Department of Health and Human Services or any other federal agency.
“VA, like so many medical facilities across this nation, is in a race to keep patients alive during this pandemic, and we are using as many tools as we can,” the VA told Schumer.
Reporting by David Morgan; Editing by Andy Sullivan and Sonya Hepinstall
Our Standards: The Thomson Reuters Trust Principles.